Akebia Therapeutics (AKBA) Gross Margin (2018 - 2026)
Akebia Therapeutics (AKBA) reported Gross Margin of 77.05% for Q1 2026, down 965.0% year-over-year from 8.91% in Q1 2025, and down 1.53% quarter-over-quarter from 78.25% in Q4 2025.
Akebia Therapeutics (AKBA) Gross Margin (2018 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 9 years of Gross Margin data on file, last reported at 77.05% in Q1 2026.
- Gross Margin for Q1 2026 came in at 77.05%, down 965.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 81.01% (up 2765.0% YoY), and the FY2025 annual result was 83.29%, up 2273.0% from the prior year.
- Gross Margin fell to 77.05% in Q1 2026 per AKBA's latest filing, from 78.25% in the prior quarter.
- Over five years, Gross Margin peaked at 122.3% in Q4 2022 and troughed at 1.94% in Q4 2024.
- A 5-year average of 69.97% and a median of 77.05% in 2026 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2024 and 2025: Gross Margin slumped 6872 bps in 2024, then soared 8018 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 122.3% in 2022, then sank by 45 bps to 66.79% in 2023, then sank by 103 bps to 1.94% in 2024, then surged by 4142 bps to 78.25% in 2025, then decreased by 2 bps to 77.05% in 2026.
- Business Quant data shows AKBA's Gross Margin at 77.05% in Q1 2026, 78.25% in Q4 2025, and 84.03% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 49.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 71.66% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 82.93% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 49.50% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 98.31% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.26% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -293.83% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 65.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 61.20% |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | 77.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.05% |
| Dec 31, 2025 | 78.25% |
| Sep 30, 2025 | 84.03% |
| Jun 30, 2025 | 84.12% |
| Mar 31, 2025 | 86.70% |
| Dec 31, 2024 | -1.94% |
| Sep 30, 2024 | 62.16% |
| Jun 30, 2024 | 60.94% |
| Mar 31, 2024 | 92.04% |
| Dec 31, 2023 | 66.79% |
| Sep 30, 2023 | 78.60% |
| Jun 30, 2023 | 85.33% |
| Mar 31, 2023 | 72.06% |
| Dec 31, 2022 | 122.30% |
| Sep 30, 2022 | 39.91% |
| Jun 30, 2022 | 57.05% |
| Mar 31, 2022 | 44.15% |
| Dec 31, 2021 | 107.62% |
| Sep 30, 2021 | 67.30% |
| Jun 30, 2021 | 17.82% |